Crestchem Q4 FY26 Results: PAT Rs 2.22 Cr

Crestchem Q4 FY26 results were declared on May 26, 2026. The company reported PAT of Rs 2.22 crore for the quarter ended March 31, 2026. Revenue from operations was Rs 26.6 crore, for the quarter ended March 31, 2026. Results are on a standalone basis. Crestchem is a Specialty Chemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Crestchem Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 26.6 crore	Rs N/A crore	N/A
Net Profit	2.22	N/A	N/A
Basis	Standalone

Note: FY26 profit Rs 2.22 Cr. Revenue Rs 26.6 Cr. Specialty chemical products company. Verify from BSE/NSE audited filings before investment decisions.

Crestchem Q4 FY26 Performance Analysis

The Crestchem Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The company delivered results reflecting current sector conditions. Crestchem operates in the Specialty Chemicals sector, supported by India’s GDP growth above 6.5% and domestic demand in FY26.

Revenue of Rs 26.6 crore was for the quarter ended March 31, 2026. Stable revenue reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Crestchem Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 26.6 crore in Crestchem Q4 FY26 was for the quarter ended March 31, 2026. Stable revenue reflects consistent operational delivery. The January to March quarter is the fiscal year-end period characterised by strong execution cycles across Indian companies.

Profitability and Margin Trends

The Crestchem Q4 FY26 PAT of Rs 2.22 crore for the quarter ended March 31, 2026. Stable profitability reflects consistent operational execution.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit conditions. The Specialty Chemicals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. Consistent revenue growth and margin expansion remain the strategic priorities.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Sector Performance and Peer Comparison

The Crestchem Q4 FY26 results come at a time when Indian corporate earnings for Q4 FY26 reflect the strength of India’s domestic consumption story. Companies across sectors reported their January to March 2026 quarter results on May 26, 2026, providing investors with a comprehensive view of FY26 corporate performance. Crestchem’s results contribute to this broader earnings picture. Indian equities have benefited from strong institutional investor participation, stable macro fundamentals, and a supportive RBI monetary policy environment during FY26, creating a positive backdrop for listed companies across market capitalisations.

Key Investor Takeaways from Crestchem Q4 FY26

For investors tracking Crestchem, the Q4 FY26 results provide important data points on revenue trajectory, profitability trends, and operational efficiency. Key metrics to evaluate include revenue growth sustainability, margin direction, working capital management, and debt levels. The company’s performance relative to its sector peers and its ability to deliver consistent shareholder returns in FY27 will be closely monitored. Management’s guidance on order book, capacity utilisation, and strategic priorities during the results discussion will shape near-term investor sentiment for Crestchem shares.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.